keyword
https://read.qxmd.com/read/38656312/association-of-changes-in-vector-length-with-changes-in-left-ventricular-mass-among-patients-on-maintenance-hemodialysis-a-secondary-analysis-of-the-frequent-hemodialysis-network-daily-trial
#1
JOURNAL ARTICLE
Enass Elsayed, Youssef M K Farag, Katherine Scovner Ravi, Glenn M Chertow, Finnian R Mc Causland
BACKGROUND: Hypervolemia is thought to be a major contributor to higher left ventricular mass (LVM), a potent predictor for cardiovascular mortality among patients on maintenance hemodialysis. We hypothesized that a decrease in vector length (a bioimpedance proxy of hypervolemia) would be associated with an increase in LVM. METHODS: Using data from the Frequent Hemodialysis Network Daily Trial (n=160) we used linear regression to assess the association of changes in vector length from baseline to month 12 with changes in magnetic resonance imaging (MRI) measures of LVM and other cardiac parameters...
April 24, 2024: Kidney360
https://read.qxmd.com/read/38653633/single-pill-combination-for-treatment-of-hypertension-just-a-matter-of-practicality-or-is-there-a-real-clinical-benefit
#2
REVIEW
A Coca, S P Whelton, M Camafort, J P López-López, E Yang
Elevated blood pressure (BP) is the largest contributor to the incident cardiovascular disease worldwide. Despite explicit guideline recommendations for the diagnosis and management of hypertension, a large proportion of patients remain undiagnosed, untreated, or treated but uncontrolled. Inadequate BP control is associated with many complex factors including patient preference, physician's inertia, health systems disparities, and poor adherence to prescribed antihypertensive drug treatment. The primary driver for reduced cardiovascular morbidity and mortality is lowering of BP ''per se'' and not class effects of specific pharmacotherapies...
April 22, 2024: European Journal of Internal Medicine
https://read.qxmd.com/read/38644253/-analysis-of-long-term-prognosis-and-risk-factors-in-patients-with-dilated-cardiomyopathy
#3
JOURNAL ARTICLE
S Y Zhang, S Q Gao, Z Y Wang, M Wu, Z Tian, S Y Zhang
Objective: To investigate the risk factors and long-term prognosis of major adverse cardiovascular events(MACEs) in patients with dilated cardiomyopathy (DCM). Methods: This study was a single-center retrospective cohort study. Clinical information from 300 patients with DCM hospitalized in Peking Union Medical College Hospital from April 2013 to April 2023 was collected. Based on echocardiography results, the patients were divided into two groups: isolated DCM and DCM with left ventricular non-compaction cardiomyopathy (LVNC)...
April 24, 2024: Zhonghua Xin Xue Guan Bing za Zhi
https://read.qxmd.com/read/38643434/a-case-report-and-literature-review-of-iga-nephropathy-presenting-as-nephrotic-syndrome-in-polycythemia-vera
#4
JOURNAL ARTICLE
R Rajasekar, R Nandakumar, Saurav P Singhvi, Gerry George Mathew, V Jayaprakash, K Mythili
A 66-year-old non-smoker presented with a 2-week history of new-onset pedal oedema and gross haematuria. On evaluation, he was found to be hypertensive and oedematous with a haemoglobin of 19.1 g/dl, platelet count of 546,000/mm3 , and creatinine of 2.6 mg/dl. Urine examination revealed abundant RBCs with 3+ albumin on three separate occasions. His 24-h urine protein level was 3830 mg/day, with a serum cholesterol level of 303 mg/dl. Secondary erythrocytosis and thrombocytosis tests were negative...
April 21, 2024: CEN Case Reports
https://read.qxmd.com/read/38643208/initiation-and-continuation-of-pharmacological-therapies-in-patients-hospitalized-for-heart-failure-in-japan
#5
JOURNAL ARTICLE
Suguru Okami, Coralie Lecomte, Hanaya Raad, Mireia Aguila, Zuzana Mohrova, Makiko Takeichi, Takanori Tsuchiya, Christoph Ohlmeier, Thomas Evers, Alexander Michel
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF drug utilization patterns in 6 months before and after hospitalizations for HF. The adherence to newly initiated HF medications was evaluated based on the proportion of days covered (PDC) and persistence as continuous treatment episodes among new users. The study included 9091 patients hospitalized for HF between January 2016 and September 2019, including 2735 (30...
April 20, 2024: Scientific Reports
https://read.qxmd.com/read/38642964/should-renin-angiotensin-system-inhibitors-be-held-prior-to-major-surgery
#6
EDITORIAL
Matthieu Legrand
Many patients undergoing surgical procedures have a history of hypertension, diabetes mellitus, heart failure, or a combination. Often, these conditions involve the chronic use of a renin-angiotensin system inhibitor, including angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Observational studies have suggested that continuing ACEIs/ARBs before major noncardiac surgery can increase the risk of intraoperative hypotension, which might drive postoperative complications such as acute kidney injury, myocardial injury, or stroke...
May 2024: British Journal of Anaesthesia
https://read.qxmd.com/read/38640337/role-and-molecular-mechanism-of-salvia-miltiorrhiza-associated-with-chemical-compounds-in-the-treatment-of-diabetes-mellitus-and-its-complications-a-review
#7
JOURNAL ARTICLE
Jiajie Li, Jinxing Liu, Weibing Shi, Jinchen Guo
Diabetes mellitus (DM) is one of the most prevalent diseases worldwide, greatly impacting patients' quality of life. This article reviews the progress in Salvia miltiorrhiza, an ancient Chinese plant, for the treatment of DM and its associated complications. Extensive studies have been conducted on the chemical composition and pharmacological effects of S miltiorrhiza, including its anti-inflammatory and antioxidant activities. It has demonstrated potential in preventing and treating diabetes and its consequences by improving peripheral nerve function and increasing retinal thickness in diabetic individuals...
April 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38637829/ace-inhibitors-and-angiotensin-receptor-blockers-differentially-alter-the-response-to-angiotensin-ii-treatment-in-vasodilatory-shock
#8
JOURNAL ARTICLE
Daniel E Leisman, Damian R Handisides, Laurence W Busse, Mark C Chappell, Lakhmir S Chawla, Michael R Filbin, Marcia B Goldberg, Kealy R Ham, Ashish K Khanna, Marlies Ostermann, Michael T McCurdy, Christopher D Adams, Tony N Hodges, Rinaldo Bellomo
BACKGROUND: Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) medications are widely prescribed. We sought to assess how pre-admission use of these medications might impact the response to angiotensin-II treatment during vasodilatory shock. METHODS: In a post-hoc subgroup analysis of the randomized, placebo-controlled, Angiotensin Therapy for High Output Shock (ATHOS-3) trial, we compared patients with chronic angiotensin-converting enzyme inhibitor (ACEi) use, and patients with angiotensin receptor blocker (ARB) use, to patients without exposure to either ACEi or ARB...
April 18, 2024: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/38634468/for-debate-the-2023-european-society-of-hypertension-guidelines-cause-for-concern
#9
JOURNAL ARTICLE
Eduard Shantsila, D Gareth Beevers, Gregory Y H Lip
Originally, the beta-blockers were equally ranked alongside the other antihypertensive drug classes. Things changed when two major long-term randomized controlled trials, ASCOT-BPLA and LIFE showed that the patients receiving the beta-blockers based regimes suffered 25-30% more strokes than those receiving a calcium channel blocker based regime or an angiotensin receptor blocker based regime. The inferiority of the beta-blockers at stroke prevention was not due to differences in blood pressure control during the follow-up period in both trials...
April 15, 2024: Journal of Hypertension
https://read.qxmd.com/read/38630049/advancements-in-diabetic-kidney-disease-management-integrating-innovative-therapies-and-targeted-drug-development
#10
REVIEW
Shaarav Ghose, Matthew Satariano, Saichidroopi Korada, Thomas Cahill, Raghav Shah, Rupesh Raina
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and affects approximately 40% of diabetic individuals. Cases of DKD continue to rise globally as the prevalence of diabetes mellitus increases, with an estimated 415 million people living with diabetes in 2015 and a projected 642 million by 2040. DKD is associated with significant morbidity and mortality, representing 34% and 36% of all chronic kidney disease deaths in men and women, respectively. Common co-morbidities including hypertension and ageing-related nephron loss further complicate disease diagnosis and progression...
April 17, 2024: American Journal of Physiology. Endocrinology and Metabolism
https://read.qxmd.com/read/38629353/the-association-between-use-of-renin-angiotensin-aldosterone-system-inhibitors-and-the-risk-and-mortality-of-pancreatic-cancer-a-systematic-review-and-meta-analysis
#11
Rasoul Rahimi, Seyed Mahmood Reza Hashemi Rafsanjani, Saeid Heidari-Soureshjani, Catherine Mt Sherwin, Karamali Kasiri
BACKGROUND: Pancreatic Cancer (PC) is one of the most malignant tumors and highly invasive neoplasms around the world. OBJECTIVE: This systematic review and meta-analysis aims to study the relationship between the use of renin-angiotensin-aldosterone system inhibitors and the incidence and mortality of PC. METHODS: The electronic search was conducted systematically until October 10, 2023. in databases, including Scopus, Web of Science (WOS), PubMed/MEDLINE, Cochrane Library, and Embase...
April 16, 2024: Curr Rev Clin Exp Pharmacol
https://read.qxmd.com/read/38627670/review-on-epidemiology-disease-burden-and-treatment-patterns-of-iga-nephropathy-in-select-apac-countries
#12
REVIEW
Omer Zaidi, Fen Du, Zhaoli Tang, Sandipan Bhattacharjee, Kristin Pareja
BACKGROUND: Immunoglobulin type A (IgA) nephropathy is the most common primary glomerulonephritis (GN) worldwide with higher rates in East and Pacific Asia compared to North America and Europe. Despite high reported prevalence of IgAN in these countries, the overall disease prevalence across Asia is not available. Treatment patterns of IgAN patients across Asian countries have also not been summarized. The aim of this study was to review and summarize evidence on IgA nephropathy prevalence, treatment patterns, and humanistic and economic burden in mainland China, Taiwan, South Korea, Japan, and Australia...
April 16, 2024: BMC Nephrology
https://read.qxmd.com/read/38623467/valsartan-mitigates-the-progression-of-methotrexate-induced-acute-kidney-injury-in-rats-via-the-attenuation-of-renal-inflammation-and-oxidative-stress
#13
JOURNAL ARTICLE
Dina Kutbi, Riyadh S Almalki
BACKGROUND: Methotrexate (MTX) is a folic acid antagonist, commonly administered for the treatment of a variety of cancers. However, methotrexate toxicity including bone marrow suppression and hepatic and renal toxicity limits its use. Angiotensin AT1 receptor blockers including Valsartan (Val) possess the ability to ameliorate MTX-induced toxicity through various mechanisms. In this study, we explored the potential reno-protective effects of Val against MTX-induced acute kidney injury in rats...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38622720/the-role-of-the-brain-renin-angiotensin-system-in-parkinson%C3%A2-s-disease
#14
REVIEW
Jose Luis Labandeira-Garcia, Carmen M Labandeira, Maria J Guerra, Ana I Rodriguez-Perez
The renin-angiotensin system (RAS) was classically considered a circulating hormonal system that regulates blood pressure. However, different tissues and organs, including the brain, have a local paracrine RAS. Mutual regulation between the dopaminergic system and RAS has been observed in several tissues. Dysregulation of these interactions leads to renal and cardiovascular diseases, as well as progression of dopaminergic neuron degeneration in a major brain center of dopamine/angiotensin interaction such as the nigrostriatal system...
April 15, 2024: Translational Neurodegeneration
https://read.qxmd.com/read/38621576/association-between-visit-frequency-continuity-of-care-and-pharmacy-fill-adherence-in-heart-failure-patients
#15
JOURNAL ARTICLE
Carine E Hamo, Amrita Mukhopadhyay, Xiyue Li, Yaguang Zheng, Ian M Kronish, Rumi Chunara, John Dodson, Samrachana Adhikari, Saul Blecker
BACKGROUND: Despite advances in medical therapy for heart failure with reduced ejection fraction (HFrEF), major gaps in medication adherence to guideline-directed medical therapies (GDMT) remain. Greater continuity of care may impact medication adherence and reduced hospitalizations. METHODS: We conducted a cross-sectional study of adults with a diagnosis of HF and EF≤40% with ≥2 outpatient encounters between 1/1/2017 and 10/1/2021, prescribed ≥1 of the following GDMT: 1) Beta Blocker, 2) Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker/Angiotensin Receptor Neprilysin Inhibitor, 3) Mineralocorticoid Receptor Antagonist, 4) Sodium Glucose Cotransporter-2 Inhibitor...
April 13, 2024: American Heart Journal
https://read.qxmd.com/read/38619824/electronic-health-record-population-health-management-for-chronic-kidney-disease-care-a-cluster-randomized-clinical-trial
#16
JOURNAL ARTICLE
Manisha Jhamb, Melanie R Weltman, Susan M Devaraj, Linda-Marie Ustaris Lavenburg, Zhuoheng Han, Alaa A Alghwiri, Gary S Fischer, Bruce L Rollman, Thomas D Nolin, Jonathan G Yabes
IMPORTANCE: Large gaps in clinical care in patients with chronic kidney disease (CKD) lead to poor outcomes. OBJECTIVE: To compare the effectiveness of an electronic health record-based population health management intervention vs usual care for reducing CKD progression and improving evidence-based care in high-risk CKD. DESIGN, SETTING, AND PARTICIPANTS: The Kidney Coordinated Health Management Partnership (Kidney CHAMP) was a pragmatic cluster randomized clinical trial conducted between May 2019 and July 2022 in 101 primary care practices in Western Pennsylvania...
April 15, 2024: JAMA Internal Medicine
https://read.qxmd.com/read/38619761/impact-of-prior-antihypertensive-treatment-on-covid-19-outcomes-by-active-ingredient
#17
JOURNAL ARTICLE
Rosa María García-Álvarez, Maruxa Zapata-Cachafeiro, Irene Visos-Varela, Almudena Rodríguez-Fernández, Samuel Pintos-Rodríguez, Maria Piñeiro-Lamas, Teresa M Herdeiro, Adolfo Figueiras, Angel Salgado-Barreira
OBJECTIVES: To assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk of hospitalization and mortality), progression of and susceptibility to COVID-19. METHODS: We conducted a multiple population-based case-control study in Galicia (north-west Spain). The study data were sourced from medical, administrative and clinical databases...
April 15, 2024: Inflammopharmacology
https://read.qxmd.com/read/38616212/systematic-review-article-new-drug-strategies-for-treating-resistant-hypertension-the-importance-of-a-mechanistic-personalized-approach
#18
REVIEW
Giulia Nardoianni, Barbara Pala, Alessandra Scoccia, Massimo Volpe, Emanuele Barbato, Giuliano Tocci
Resistant hypertension (RHT) is characterized by persistently high blood pressure (BP) levels above the widely recommended therapeutic targets of less than 140/90 mmHg office BP, despite life-style measures and optimal medical therapies, including at least three antihypertensive drug classes at maximum tolerated dose (one should be a diuretic). This condition is strongly related to hypertension-mediated organ damage and, mostly, high risk of hospitalization due to hypertension emergencies or acute cardiovascular events...
April 14, 2024: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://read.qxmd.com/read/38614313/unlocking-sex-specific-therapies-in-aortic-stenosis-a-leap-forward-with-angiotensin-ii-receptor-blockers
#19
EDITORIAL
Elizabeth Hillier, Judy Luu
No abstract text is available yet for this article.
April 11, 2024: Canadian Journal of Cardiology
https://read.qxmd.com/read/38612779/molecular-targets-of-novel-therapeutics-for-diabetic-kidney-disease-a-new-era-of-nephroprotection
#20
REVIEW
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, oxidative stress, inflammatory pathway, fibrotic signaling, and hemodynamic mechanisms) appears to drive the onset and progression of DKD. A growing understanding of the pathogenetic mechanisms, and the development of new therapeutics, is opening the way for a new era of nephroprotection based on precision-medicine approaches...
April 3, 2024: International Journal of Molecular Sciences
keyword
keyword
10488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.